Safety assessment of anticancer drugs in association with radiotherapy in metastatic malignant melanoma: a real-life report-Reference-Cited by-同舟云学术

Safety assessment of anticancer drugs in association with radiotherapy in metastatic malignant melanoma: a real-life report

Published:2019-02-26 Issue:5 Volume:83 Page:881-892
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Couty Emmanuelle,Vallard Alexis^ORCID,Sotton Sandrine,Ouni Sarra,Garcia Max-Adrien,Espenel Sophie,Rancoule Chloe,Ben Mrad Majed,Biron Anne-Catherine,Perrot Jean-Luc,Langrand-Escure Julien,Magné Nicolas

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/article/10.1007/s00280-019-03806-5/fulltext.html

Reference46 articles.

1. Garbe C, Peris K, Hauschild A, Saiag P, Middleton M, Bastholt L, Grob J-J, Malvehy J, Newton-Bishop J, Stratigos AJ, Pehamberger H, Eggermont AM, European Dermatology Forum (EDF) et al (2016) Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline—update 2016. Eur J Cancer Oxf Engl 1990 63:201–217. https://doi.org/10.1016/j.ejca.2016.05.005

2. Guillot B, Dalac S, Denis MG, Dupuy A, Emile JF, De La Fouchardiere A, Hindie E, Jouary T, Lassau N, Mirabel X, Piperno Neumann S, De Raucourt S, Vanwijck R (2017) French updated recommendations in Stage I to III melanoma treatment and management. J Eur Acad Dermatol Venereol 31:594–602. https://doi.org/10.1111/jdv.14064

3. Coit DG, Thompson JA, Algazi A, Andtbacka R, Bichakjian CK, Carson WE, Daniels GA, DiMaio D, Fields RC, Fleming MD, Gastman B, Gonzalez R, Guild V et al (2016) NCCN guidelines insights: melanoma, version 3.2016. J Natl Compr Cancer Netw 14:945–958

4. Ascierto PA, McArthur GA, Dréno B, Atkinson V, Liszkay G, Di Giacomo AM, Mandalà M, Demidov L, Stroyakovskiy D, Thomas L, de la Cruz-Merino L, Dutriaux C, Garbe C et al (2016) Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol 17:1248–1260. https://doi.org/10.1016/S1470-2045(16)30122-X

5. Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, Lichinitser M, Dummer R, Grange F, Mortier L, Chiarion-Sileni V, Drucis K, Krajsova I et al (2015) Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 372:30–39. https://doi.org/10.1056/NEJMoa1412690

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Late Onset of Cardiac Metastasis of a Melanoma following Nivolumab Immunotherapy;Case Reports in Oncology;2022-06-27

2. Effectiveness and safety of immune checkpoint inhibitors in combination with palliative radiotherapy in advanced melanoma: A systematic review;Critical Reviews in Oncology/Hematology;2021-11

3. Safety of radiosurgery concurrent with systemic therapy (chemotherapy, targeted therapy, and/or immunotherapy) in brain metastases: a systematic review;Cancer and Metastasis Reviews;2021-01-04

4. Clinical Outcomes of Immune Checkpoint Blocker Therapy for Malignant Melanoma in Korean Patients: Potential Clinical Implications for a Combination Strategy Involving Radiotherapy;Cancer Research and Treatment;2020-07-15

5. Vemurafenib;Reactions Weekly;2019-05